EC Microbiology

Introduction: Diabetes is the most common cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in the world. Both type 1 and type 2 diabetic patients are commonly to have Chronic kidney disease (CKD), which defined as three months history of a glomerular filtration rate (GFR) reduction and/or an increased albumin excretion in the urine. The prevalence of diabetes in the United States has raised from 6 to 10 per cent over the last 20 years. While the percentage of diabetic patients CKD has maintained.

Aim of the Work: An overview of diabetic kidney disease (DKA), also known as diabetic nephropathy, will be presented in this paper.

Methodology: This paper is a nonsystematic review of medical literature regarding diabetic kidney disease. The literature search was conducted by using PubMed database and google scholar search engine.

Conclusion: Diabetic kidney disease and CKD are more common in women, African American, and Latino. Obesity is considered an essential risk factor for type 2 diabetes and coexists with type 1 diabetes. Persistently raised levels of albuminuria and/or persistent (eGFR) reduction are considered the most frequent clinical finding. Majority of patients’ presentation are asymptomatic for that, regular and routine checkup is the method of detection. If non-diabetic kidney disease is suspected, a kidney biopsy should have conducted. Management of DKD include general measures such as controlling blood pressure, glycemic control, and lifestyle modification. Angiotensin inhibition is the drug of choice in cases with severe albuminuria.

Keywords: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetes Mellitus Chronic Complications

1. Olivarius Nde F., et al. “Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study “Diabetes Care in General Practice”, Denmark. Di”. Diabetologia 10 (1993): 1007-1016.
2. Mogensen CE., et al. “The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy”. Diabetes2 (1983): 64.
3. Krolewski AS., et al. “Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria”. Diabetes Care 37 (2014): 226.
4. Krolewski AS. “Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes”. Diabetes Care 38 (2015): 954.
5. Afkarian M., et al. “Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014”. The Journal of the American Medical Association 316 (2016): 602.
6. Afkarian M., et al. “Kidney disease and increased mortality risk in type 2 diabetes”. Journal of the American Society of Nephrology 24 (2013): 302.
7. Mayer-Davis EJ., et al. “Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012”. The New England Journal of Medicine 376 (2017): 1419.
8. Dabelea D., et al. “Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood”. The Journal of the American Medical Association 317 (2017): 825.
9. Kahkoska AR., et al. “The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes”. Journal of Diabetes and its Complications 32 (2018): 1160.
10. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System - United States (2018).
11. Burrows NR., et al. “Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline”. Diabetes Care 33 (2010): 73.
12. United States Renal Data System. USRDS 2018 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, editor, National Institutes of Health, National Institute of Diabetes (2018).
13. Tsai WC., et al. “Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis”. Medicine (Baltimore) 95 (2016): e3013.
14. Sharma K., et al. “Adiponectin regulates albuminuria and podocyte function in mice”. Journal of Clinical Investigation 118 (2008): 1645.
15. Liao D., et al. “Cigarette smoking as a risk factor for diabetic nephropathy: A systematic review and meta-analysis of prospective cohort studies”. PLoS One 14 (2019): e0210213.
16. Ku E., et al. “Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes”. Diabetes Care 39 (2016): 2218.
17. Guan M., et al. “Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans”. Human Genomics 13 (2019): 21.
18. Kruzel-Davila E., et al. “APOL1 nephropathy: from gene to mechanisms of kidney injury”. Nephrology Dialysis Transplantation 31 (2016): 349.
19. American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019”. Diabetes Care 42 (2019): S124.
20. “KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease”. The American Journal of Kidney Diseases 49 (2007): S12.
21. O’Neill WM Jr., et al. “Hematuria and red cell casts in typical diabetic nephropathy”. The American Journal of Medicine 74 (1983): 389.
22. Jiang S., et al. “Accuracy of hematuria for predicting non-diabetic renal disease in patients with diabetes and kidney disease: A systematic review and meta-analysis”. Diabetes Research and Clinical Practice 143 (2018): 288.
23. Ali MK., et al. “Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014”. The Lancet Diabetes and Endocrinology 6 (2018): 392.
24. Fiorentino M., et al. “Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies”. Nephrology Dialysis Transplantation 32 (2017): 97.
25. Gæde P., et al. “Effect of a multifactorial intervention on mortality in type 2 diabetes”. The New England Journal of Medicine 358 (2008): 580.
26. An Y., et al. “Renal histologic changes and the outcome in patients with diabetic nephropathy”. Nephrology Dialysis Transplantation 30 (2015): 257.
27. Mazzucco G., et al. “Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies”. The American Journal of Kidney Diseases 39 (2002): 713.
28. Jamerson K., et al. “Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients”. The New England Journal of Medicine 359 (2008): 2417.
29. DCCT/EDIC Research Group de Boer IH., et al. “Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes”. The New England Journal of Medicine 365 (2011): 2366.
30. Flynn C and Bakris GL. “Noninsulin glucose-lowering agents for the treatment of patients on dialysis”. Nature Reviews Nephrology 9 (2013): 147.
31. Barnett AH., et al. “Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy”. The New England Journal of Medicine 351 (2004): 1952.
32. Dekkers CCJ., et al. “Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease”. Nephrology Dialysis Transplantation 33 (2018): 2005.
33. Salah HM., et al. “Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials”. American Heart Journal 232 (2021): 10.
34. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease”. Kidney International 98 (2020): S1.
35. Agarwal R., et al. “Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine”. European Heart Journal 42 (2021): 152.